FDA Releases Guidance on Charging for Investigational Drugs Under IND

Summary

The Food and Drug Administration (FDA) has published a guidance document addressing questions about charging for investigational drugs under an Investigational New Drug Application (IND) for clinical trials or expanded access treatment use, following a number of inquiries from industry, researchers, and patients.